Rigel Pharmaceuticals Inc (RIGL): R&D Expense
$33.30M
Year ended 2025-12-31
$43.67M
Trailing 12 months to 2026-06-30
-17.9%
3-year compound annual growth
-11.1%
5-year compound annual growth
-6.2%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $33.30M | +42.4% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $23.38M | -4.7% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $24.52M | -59.3% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $60.27M | -7.6% | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | $65.24M | +8.5% | 2024-03-05, From 2021-01-01 |
| 2020-12-31 | $60.10M | +13.6% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $52.88M | +12.8% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $46.90M | +1.4% | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | $46.27M | -27.1% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $63.45M | +1.0% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $62.83M | -7.2% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $67.70M | -10.1% | 2017-03-07, From 2014-01-01 |
| 2013-12-31 | $75.33M | -4.4% | 2016-03-08, From 2013-01-01 |
| 2012-12-31 | $78.78M | +13.6% | 2015-03-03, From 2012-01-01 |
| 2011-12-31 | $69.35M | +7.7% | 2014-03-04, From 2011-01-01 |
| 2010-12-31 | $64.39M | -29.0% | 2013-03-05, From 2010-01-01 |
| 2009-12-31 | $90.74M | n/a | 2012-03-06, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $33.30M | +42.4% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $94.79M | +55.6% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $71.53M | +36.7% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $258.78M | +7.1% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $145.64M | +75.2% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $157.70M | +26.6% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $109.27M | +46.8% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $100.64M | n/a |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $37.41M | -0.6% |
Compare RIGL, RAPP, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗